New indication concerns a combination with gemcitabine and cisplatin in first-line treatment
Updated indication restricts the use to patients whose tumours express PD-L1 CPS ≥ 1 as determined by an FDA-approved test
The ESMO Immuno-Oncology Congress 2023, where experts discuss the latest scientific developments in this fast-moving field of cancer treatment, will be held in Geneva, Switzerland, between 6-8 December, also with a virtual component
Findings from the FLAURA2 study
Findings from the European MCL Elderly study